References
- Cain B F, Atwell G J. The experimental antitumor properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. Eur J Cancer Clin Oncol 1974; 10: 539–549
- Legha S S, Keating M J, McCredie K B, et al. Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults. Blood 1982; 60: 484–490
- Arlin Z A, Sklaroff R B, Gee T S, et al. Phase I and II trial of 4′-(9-acridinylamino)-methanesulfon-m-anisidide in patients with acute leukemia. Cancer Res 1980; 40: 3304–3306
- Legha S S, Latreille J, McCredie K B, et al. Neurologic and cardiac rhythm abnormalities associated with 4′-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) therapy. Cancer Treat Rep 1979; 63: 2001–2003
- Feldman E J, Arlin Z A, Sullivan P. Preventing amsacrine-induced cardiac arrhythmias. J Clin Oncol 1987; 5: 2041
- Arlin Z A, Mehta R K, Feldman E, et al. Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia. Cancer Chemother Pharmacol 1987; 19: 163–164
- Puccio C A, Feldman E, Arlin A Z. Amsacrine is safe in patients with ventricular ectopy. Am J Hematol 1988; 28: 197–198
- Fanucchi M P, Arlin Z A. Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline car-diomyopathy with 4′ (9-acridinylamino) methanesulfon-m-anisidide (AMSA). Cancer Chemother Pharmacol 1983; 10: 27–28
- Arlin Z A, Berman E, Gee T S. Results of a comparative trial of amsacrine and daunorubicin in combination with cytarabine and thioguanine in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Blood 1984; 64: 161a
- Jacobs A D, Gale R P. Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults. N Engl J Med 1984; 311: 1219–1231
- Arlin Z A, Flomenberg N, Gee T S, et al. Treatment of acute leukemia in relapse with 4′-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine. Cancer Clin Trials 1981; 4: 317–321
- Hines J D, Oken M M, Mazza J J, et al. High dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol 1984; 2: 545–549
- Zittoun R, Stryckmans J BP, Lowenberg B, et al. Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treat Rep 1985; 69: 1447–1448
- Arlin Z A, Ahmed T, Mittelman A. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. J Clin Oncol 1987; 5: 371–375
- Feldman E, Puccio M, Ahmed T, et al. Central nervous system (CNS) toxicity with high-dose cytarabine (HiDAc): A comparison of two different regimens. J Clin Oncol 1988, in press
- Keating M J, Gehan E A, Smith T L. A strategy for evaluation of new treatments in untreated patients: Application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 1987; 5: 710–721
- Weil M, Auclerc M F, Schaison G, et al. Activite clinique de la m-AMSA et de l'association de m-AMSA et de cytosine arabinoside. Nouv Presse Med 1982; 11: 2911–2914
- Arlin A, Feldman E, Kempin S. Amsacrine with high dose cytarabine is high effective therapy for refractory and relapsed acute lymphoblastic leukemia (ALL) in adults. Blood 1988; 72: 433–435